Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gross Profit | $1,158.0M | $1,768.1M | $2,592.8M | $3,461.3M | $4,208.5M | $5,415.8M | $6,079.5M | $6,261.0M | $7,231.2M | $8,343.2M | $21.1B | $28.6B | $26.1B | $21.7B | $17.3B | $17.8B | $20.1B | $20.7B | $21.6B | $20.6B |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Gilead Sciences, Inc.'s last 12-month Gross Profit is $22.1B, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Gilead Sciences, Inc.'s Gross Profit growth was 2.2%. The average annual Gross Profit growth rates for Gilead Sciences, Inc. have been 2.3% over the past three years, 4.4% over the past five years.
Over the last year, Gilead Sciences, Inc.'s Gross Profit growth was 2.2%, which is higher than industry growth of 0.3%. It indicates that Gilead Sciences, Inc.'s Gross Profit growth is Good.